One Lentiviral Platform.
Two Paths to Advance Cures.
Weeks from Project Start to First Vector
<
0
Hidden Royalty Fees; Full Cost Model Transparency
0
Cost reduction of GMP batch vs. industry AVG
0
%
Custom Lentiviral vector design built for your specific therapeutic payload
- End-to-end platform-based vector engineering with CGMP execution in mind
- Transparent timelines and fast iteration cycles from RUO to CGMP
- Streamlined low-cost CGMP vector manufacturing approach
- Platform designed by the team behind the first lentiviral CAR-T to reach patients
- Simplified commercial terms for development, manufacturing, and commercialization
Use Cases
Custom Lentiviral vector design built for your specific therapeutic payload
A complete, ready-to-deploy solution for generic CAR-T manufacturing
- Fully characterized CGMP-ready lentiviral vectors
- Streamlined protocols, reagents, and process workflows for decentralized generic CAR-T manufacturing
- Optimized Anti-CD19 and anti-BCMA CAR constructs available
- Built-in documentation to simplify regulatory filings
- Transparent licensing with a defined path from vector to commercial cell therapy manufacturing, terms disclosed before you commit.
Use Cases
Rapid, cost-effective generic autologous CAR-T programs
Break the Gravity of Legacy CDMOs.
Built by Lentiviral Pioneers with Decades of Proven Expertise
Platform-based technology developed by the team behind the first lentiviral CAR-T therapy.
Lower Cost, Greater Access
Streamlined processes that cut costs and expand access to both generic and novel cell & gene therapies.
Faster from RUO to CGMP
Platform approach and construct optimization expertise accelerate candidate selection and clinical readiness.
Manufacture Anywhere
No lock-in to proprietary systems; designed for decentralized, flexible cell therapy manufacturing models.
Global Focus
Designed for modular manufacturing to reach more patients in more places.
Featured Content
Featured Resource
- Insights / White Paper
Learn how platform-driven lentiviral manufacturing can accelerate development timelines, reduce costs, and expand access to transformative cell therapies.
Featured Resource
- Webinars On-demand
The promise of cell and gene therapy (CGT) is no longer a distant dream. Today, it’s changing lives by targeting the root causes of disease.
Featured Resource
- Articles / Interview
Interview with Vector BioMed CEO Boro Dropulić, PhD, MBA, and COO Mike Kadan, PhD, MBA, - Rethinking lentiviral manufacturing for cell and gene therapies: from platform design to point-of-care delivery.
Featured Resource
- Webinars On-demand
Optimizing Lentiviral Vector Development: Strategies for Efficiency and Affordability in Cell and Gene Therapy.